SCHEMBL31172644

SCHEMBL31172644

O=C(Oc1c(F)c(F)c(F)c(F)c1F)c1ccc(Cn2cccn2)c(OC(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KAT7 O95251 4/20 0.42
▸ KAT6A Q92794 4/20 0.42
▸ KAT6B Q8WYB5 3/20 0.42
▸ PDE4B Q07343 2/20 0.41
▸ HTT P42858 2/20 0.37
▸ ADRB2 P07550 1/20 0.37
▸ ADRB1 P08588 1/20 0.37
▸ ADRB3 P13945 1/20 0.37
▸ HDAC1 Q13547 1/20 0.37
▸ HDAC6 Q9UBN7 1/20 0.37
▸ PDE4A P27815 1/20 0.37
▸ PDE4C Q08493 1/20 0.37
▸ PDE4D Q08499 1/20 0.37
▸ KLKB1 P03952 1/20 0.36
▸ LMNA P02545 3/20 0.36
▸ THRB P10828 1/20 0.36
▸ RAB9A P51151 1/20 0.35
▸ KMT2A Q03164 4/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172674 0.88 KAT7 (0.48) KAT7KAT6AKAT6BPDE4BHTT
SCHEMBL31172672 0.88 KAT7 (0.42) KAT7KAT6AKAT6BHTTHDAC1
SCHEMBL31172694 0.85 KLKB1 (0.38) KAT7KAT6AKAT6BHTTADRB2
SCHEMBL31172703 0.85 HTT (0.53) KAT7KAT6AKAT6BPDE4BHTT
SCHEMBL553315 0.75 KLKB1 (0.47) KAT7KAT6AKAT6BHTTADRB2
SCHEMBL31172623 0.74 BRD4 (0.36) KAT7KAT6AKAT6BHTTADRB2
SCHEMBL31172618 0.73 HDAC1 (0.42) KAT7KAT6AKAT6BHTTADRB2
SCHEMBL17221669 0.73 KLKB1 (0.50) KAT7KAT6AKAT6BHTTHDAC1
SCHEMBL31691444 0.73 HDAC1 (0.43) KAT7KAT6AKAT6BHTTADRB2
SCHEMBL31172590 0.73 KLKB1 (0.41) KAT7KAT6AKAT6BHTTADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 — — EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KAT7 5/4885KAT6A 1/4885KAT6B 3/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B KAT7 5/4885KAT6A 1/4885KAT6B 3/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KAT7 4/4885KAT6A 1/4885KAT6B 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback